Skip to content

Disease Modification Outcomes in Diabetes: a Delphi Study

Disease Modification Outcomes in Diabetes: a Delphi Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07201532
Enrollment
300
Registered
2025-10-01
Start date
2025-09-30
Completion date
2026-06-30
Last updated
2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Type 2 diabetes is a condition when the pancreas does not produce enough of the hormone, insulin, or the insulin that is formed does not function effectively. This results in high blood sugar levels. Type 2 diabetes is associated with other health conditions, and people with the condition have a higher chance of dying earlier and having other complications. People with type 2 diabetes take a lot of different types of medications. The current treatments that exist aim to manage blood sugar levels, rather than affect the progression of the disease. The research involving treatments that impact the long-term progression of type 2 diabetes is sometimes hard to understand. This is because research studies measure a lot of different outcomes (outcomes are items we measure to show that the study has worked and/or it is safe). One way of improving research is to make sure that we are measuring the same outcomes, but also that these outcomes are important to people living with type 2 diabetes and healthcare professionals. This can be done by using a core outcome set (COS). A COS is a short list of outcomes that are important to researchers, healthcare professionals and people living with type 2 diabetes. The aim of this study is to design a COS for research studies for disease modification in type 2 diabetes via an e-Delphi study. The Delphi process is a structured process used for forming a consensus, where stakeholder groups provider their opinions in an iterative approach for answering questions over several rounds. This will also take place using surveys online.

Interventions

A Delphi consensus study will be undertaken to establish a core outcome set for disease modification in type 2 diabetes.

Sponsors

American Diabetes Association
CollaboratorOTHER
University of Leicester
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Participants will fall into one of two groups: 1. Healthcare practitioners and researchers working in the field of diabetes research and/or clinical care. 2. People with type 2 diabetes. All participants will be ≥18 years of age.

Exclusion criteria

1. Potential participants who are not willing to provide informed consent or participate in the Delphi study. 2. Those who are unable to understand English. 3. Those without the capability to respond to the online survey.

Design outcomes

Primary

MeasureTime frameDescription
Delphi Round 1Three to four weeksThe Delphi methodology is an interactive multi-stage process, with each stage building on the data of the previous results in order to gain consensus from the participants. This is achieved through a series of surveys interspersed with controlled feedback containing the aggregated results from all participants in the study cohort. In Delphi Round 1, participants will be asked to rate the importance of outcomes for inclusion or exclusion using a 9-point Likert scale.
Delphi Round 2Three to four weeksIn Round 2, participants will be asked to rate the importance of remaining outcomes that did not reach consensus for inclusion or exclusion in Round 1 using a 9-point Likert scale. Consensus is defined as a minimum of 70% of participants who rated an outcome as 1-3 Not important and should be excluded or 7-9 and indicates an outcome is Critical and should be included. If necessary, a third round of the survey will be administered to attempt to reach consensus on the remaining outcomes/instruments that did not do so in the previous rounds. Results will inform the development of the final COS.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026